Govt extends timeline for Global Tender for REPM scheme (See 'Corp Brief') Indian Pharmacopoeia Commission organizes Scientific Conclave (See 'Corp Brief') Scindia reviews Key Development Projects during Sikkim Visit (See 'Corp Brief') Union Minister of State for Coal & Mines reviews CMPDIL (See 'Corp Brief') Commerce Minister chairs meet on promoting fisheries exports (See 'Corp Brief') Govt reviews progress of micro Food Processing Enterprises in Leh (See 'Corp Brief') Railways carries 170% more Cement in last 4 Months (See 'Corp Brief') A&C - Later attempt by insurer to artificially split same claim into separate components of admitted and denied liability does not render unpaid component non-arbitrable: HC (See 'Legal Desk') Self-reliance and jointness must for strategic autonomy & future-ready force: RM (See 'Corp Brief') NCB launches 6-Month Online Certification Program on Advanced Concrete Technology (See 'Corp Brief') Pradhan chairs coordination forum meeting of IIMs at Ahmedabad (See 'Corp Brief') IBC - CoC's reasoned decision not to consider unsolicited post-submission addendum is within its commercial wisdom and is not liable to judicial interference absent any violation of Sec 30(2) or Sec 61(3): NCLAT (See 'Legal Desk') MoS visits Eastern Coalfields Limited (See 'Corp Brief') Department of School Education Secretary launches Bharatiya Bhasha Summer Camp in New Delhi (See 'Corp Brief') IndiaAI Mission and NHA felicitate Winners of AB PM-JAY Auto-Adjudication Hackathon (See 'Corp Brief') Jammu-Srinagar Vande Bharat Express Services serve around 45,000 Pax in first 10 Days of its Run (See 'Corp Brief') National Conference held on nationwide EV Charging Infrastructure under E-DRIVE Scheme (See 'Corp Brief') IPR - Computer-related invention which merely uses algorithm to colour-code message recipients based on message address characteristics, does not become patentable: HC (See 'Legal Desk') NHAI successfully defends arbitration claims in Panipat–Jalandhar Highway Disputes (See 'Corp Brief') Kumaraswamy announces Rs 123 Crore EV Charging Boost for Karnataka (See 'Corp Brief') Pradhan addresses Bharat Innovates 2026 High-level Diplomatic Conclave (See 'Corp Brief') AIIMS New Delhi has always been more than a hospital - a brand in itself: Nadda (See 'Corp Brief') Misc - If Union of India claims title over land on basis of old government grant and subsequent constitutional vesting, it must prove that title in fact remained vested in Government: HC (See 'Legal Desk') CCI approves acquisition of Kenvue Inc. by Kimberly-Clark (See 'Corp Brief') CCI approves Adani Power to buy stake of GVK Energy (See 'Corp Brief') IBC - If transaction was builder-linked contractual arrangement rather than pure financial debt default, Section 7 IBC proceedings cannot be used in parallel with DRT recovery proceedings: SC (See 'Legal Desk') CCI approves acquisition of stake in Llyods Engineering by Thriveni Earthmovers (See 'Corp Brief') CCI approves acquisition by CPPIB India in Ctrl S Datacenters (See 'Corp Brief') Govt pushes India Post toward Corporate-Style Efficiency (See 'Corp Brief') IPR - Use of house mark does not by itself obviate infringement or passing off: HC (See 'Legal Desk') Present petro conservation intended towards long-run capacity building: RM (See 'Corp Brief') Atal Innovation Mission hosts AIM Sumvaad- Central India to strengthen regional incubators (See 'Corp Brief') FERA - Foreign judgment is unenforceable in India as it fell within exceptions u/s 13 CPC: SC (See 'Legal Desk') Forum of Regulators celebrates 21 Years of strengthening India's Power Sector (See 'Corp Brief') A&C - Once seat of arbitration is expressly designated by agreement of parties, that seat becomes juridical home of arbitration and operates akin to exclusive jurisdiction clause: SC (See 'Legal Desk') Supreme Court lays down scenarios for lifting of Doctrine of Corporate Veil (See 'CORP EINSICHTf') Fisheries Secy visits ornamental fish brood bank in Maharashtra (See 'Corp Brief') Company Law - For purpose of maintainability of petitions u/s 397 & 398, expression ‘member' is not to be confined only to formal entry in register of members u/s 41(2): SC (See 'Legal Desk') Over 3,500 Participants compete in AB PM-JAY Hackathon (See 'Corp Brief') Scindia, Fadnavis inaugurate renovated Andheri RS Post Office as Future-Ready Service Hub (See 'Corp Brief') IBC - While subsidiary companies are separate legal entities, corporate veil may be lifted if associated companies are inextricably connected so as to form one concern: SC (See 'Legal Desk')

Print

Indian Pharmacopoeia Commission organizes Scientific Conclave

Published: May 16, 2026

By TIOLCorplaws News Service

NEW DELHI, MAY 16, 2026: THE Indian Pharmacopoeia Commission (IPC), Ministry of Health and Family Welfare, Government of India, organized a Scientific Conclave & Interactive Session on Indian Pharmacopoeia 2026 yesterday at the National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana, in collaboration with NIPER Hyderabad, Central Drugs Standard Control Organization (CDSCO), and the IDMA Telangana Chapter. The conclave focused on the theme "Significance of Indian Pharmacopoeia Reference Standards and Impurity Standards in Ensuring Pharmaceutical Quality."

The IPC, mandated with promoting the quality, safety, and rational use of medicines, continues to undertake initiatives aimed at strengthening pharmaceutical quality and safeguarding patient safety. Recognizing that the quality of medicines remains a critical component of public health protection, IPC has been consistently addressing issues related to pharmaceutical quality through scientific, regulatory, and stakeholder engagement platforms. The present conclave was organized to deliberate upon the significance of Indian Pharmacopoeia Reference Substances (IPRS) and impurity standards in ensuring the quality, safety, and efficacy of medicines.

The conference was formally inaugurated by Prof. Shailendra Saraf, Director, NIPER Hyderabad, who appreciated IPC for collaborating with academic institutions in advancing pharmaceutical quality initiatives. He highlighted that such collaborations with premier institutions, including NIPER Hyderabad and previously NIPER Ahmedabad, provide an important platform for scientific exchange and capacity building among regulators, academia, and industry stakeholders.

Dr. V. Kalaiselvan, Secretary-cum-Scientific Director, IPC, emphasized that impurity profiling and scientifically established pharmacopoeial standards are essential components in reducing adverse effects associated with pharmaceutical impurities. He reiterated IPC's commitment towards strengthening medicine quality systems and contributing to the vision of "Viksit Bharat" through robust pharmacopoeial standards and quality assurance mechanisms.

The inaugural session was attended by senior officials from IPC, CDSCO, NIPER Hyderabad, and the pharmaceutical industry. K. Narendran, Deputy Drugs Controller (India), CDSCO, Hyderabad, also addressed the gathering and highlighted the importance of harmonized standards and regulatory oversight in ensuring medicine quality.

A unique feature of the conclave was the participation of stakeholders from both the pharmaceutical quality and clinical domains. For the first time, IPC brought together experts from regulatory, analytical, industrial, and clinical backgrounds to deliberate upon the clinical implications of pharmacopoeial impurities, including their potential association with adverse drug reactions and patient safety concerns. The conclave also provided an important opportunity for pharmaceutical industries actively involved in the development, adoption, and implementation of IPRS and impurity standards to share their experiences and perspectives.

During the technical sessions, experts from IPC, CDSCO, academia, and the pharmaceutical industry deliberated upon contemporary issues related to pharmacopoeial standards, impurity control, regulatory compliance, advancements in Indian Pharmacopoeia 2026, impurity reference standards, pharmaceutical quality assurance, risk assessment approaches, and emerging global concerns in pharmaceutical impurity management and regulatory control

The conclave concluded with an interactive open discussion involving experts from IPC, CDSCO, State Licensing Authorities, academia, clinicians, researchers, and industry representatives on various aspects of pharmaceutical impurities, analytical methodologies, regulatory expectations, and implementation challenges.

The conference was well attended by regulators, pharmaceutical industry professionals, academicians, clinicians, analytical scientists, and researchers from across the country, reaffirming IPC's continued commitment towards strengthening medicine quality systems and promoting public health protection through scientifically robust pharmacopoeial standards.

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
tioltube
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.